Effect of cholecalciferol on 25-hydroxyvitamin D in people living with HIV and vitamin D deficiency: A prospective observational study

IF 2.6 4区医学 Q1 MEDICINE, GENERAL & INTERNAL

Medicina Clinica Pub Date : 2025-05-23 DOI:10.1016/j.medcli.2025.106972

Cristina Tomás , Ángeles Muñoz , Carlos Báguena , Antonia Alcaraz , Rodrigo Martínez-Rodríguez , María Dolores Hernández , María Isabel Martínez , Rubén Corral-San-Miguel , Eduardo Pons-Fuster López , Eva García-Villalba , Salvador Valero , Eva Oliver Galera , Elena Guijarro Westermeyer , Román González Hipólito , Concepción Corbalán Dólera , María del Carmen García Ros , Enrique Bernal

{"title":"Effect of cholecalciferol on 25-hydroxyvitamin D in people living with HIV and vitamin D deficiency: A prospective observational study","authors":"Cristina Tomás , Ángeles Muñoz , Carlos Báguena , Antonia Alcaraz , Rodrigo Martínez-Rodríguez , María Dolores Hernández , María Isabel Martínez , Rubén Corral-San-Miguel , Eduardo Pons-Fuster López , Eva García-Villalba , Salvador Valero , Eva Oliver Galera , Elena Guijarro Westermeyer , Román González Hipólito , Concepción Corbalán Dólera , María del Carmen García Ros , Enrique Bernal","doi":"10.1016/j.medcli.2025.106972","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>To assess the effect of oral cholecalciferol 50,000IU monthly administered in people living with HIV (PLHIV) and 25(OH)D deficiency followed over 48 weeks.</div></div><div><h3>Methods</h3><div>A prospective observational study was conducted in a cohort of 110 PLHIV with 25(OH)D levels<20ng/mL. Changes in 25(OH)D levels were evaluated at 3, 6, and 12 months of treatment. The percentages of patients who achieved 25(OH)D levels>20 and >30ng/mL and changes in bone mineral density (BMD) were assessed.</div></div><div><h3>Results</h3><div>One hundred ten PLHIV (79% men, mean age 49.46 years) were included. The mean (standard deviation, SD) time on antiretroviral treatment was 10.69 (8.31) years and all patients had a viral load<50copies/mL. The mean 25(OH)D levels of 15.10±3.22ng/mL at baseline increased significantly (<em>P</em>              <!-->IU of cholecalciferol was effective in normalizing 25(OH)D deficiency in 87% of PLHIV, without observing changes in bone mineral density.</div></div>","PeriodicalId":18578,"journal":{"name":"Medicina Clinica","volume":"165 2","pages":"Article 106972"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina Clinica","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0025775325001988","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

To assess the effect of oral cholecalciferol 50,000 IU monthly administered in people living with HIV (PLHIV) and 25(OH)D deficiency followed over 48 weeks.

Methods

A prospective observational study was conducted in a cohort of 110 PLHIV with 25(OH)D levels < 20 ng/mL. Changes in 25(OH)D levels were evaluated at 3, 6, and 12 months of treatment. The percentages of patients who achieved 25(OH)D levels > 20 and >30 ng/mL and changes in bone mineral density (BMD) were assessed.

Results

One hundred ten PLHIV (79% men, mean age 49.46 years) were included. The mean (standard deviation, SD) time on antiretroviral treatment was 10.69 (8.31) years and all patients had a viral load < 50 copies/mL. The mean 25(OH)D levels of 15.10 ± 3.22 ng/mL at baseline increased significantly (P < 0.001) to 27.89 ± 7.79 ng/mL at 3 months, 28.53 ± 8.45 ng/mL at 6 months and 27.89 ± 7.92 ng/mL at 12 months. A total of 87.27% had normal 25(OH)D levels at 12 months (>30 ng/mL in 36.1% of patients and >20 ng/mL in 51.5%). Parathormone levels (PTH) also decreased significantly. Treatment was safe and well tolerated. On the other hand, no significant changes were observed in BMD.

Conclusions

Monthly administration of 50,000 IU of cholecalciferol was effective in normalizing 25(OH)D deficiency in 87% of PLHIV, without observing changes in bone mineral density.

查看原文本刊更多论文

胆骨化醇对艾滋病毒和维生素D缺乏症患者25-羟基维生素D的影响：一项前瞻性观察研究

目的评价每月口服50,000 IU胆钙化醇对HIV （PLHIV）和25(OH)D缺乏症患者随访48周的效果。方法对110例25(OH)D水平的PLHIV患者进行前瞻性观察研究；20 ng / mL。在治疗3、6和12个月时评估25(OH)D水平的变化。达到25(OH)D水平的患者百分比>；20和30 ng/mL，评估骨矿物质密度（BMD）的变化。结果共纳入PLHIV 110例，男性79%，平均年龄49.46岁。抗逆转录病毒治疗的平均（标准差，SD）时间为10.69（8.31）年，所有患者都有病毒载量；50拷贝/毫升。基线时平均25(OH)D水平15.10±3.22 ng/mL显著升高(P <；0.001)至3个月27.89±7.79 ng/mL， 6个月28.53±8.45 ng/mL， 12个月27.89±7.92 ng/mL。共有87.27%的患者12个月时25(OH)D水平正常（36.1%的患者为30 ng/mL， 51.5%的患者为20 ng/mL）。甲状旁腺激素（PTH）水平也显著下降。治疗是安全且耐受性良好的。另一方面，骨密度没有明显变化。结论每月给予50,000 IU的胆骨化醇可有效改善87%的PLHIV患者的25(OH)D缺乏症，且未观察到骨密度的变化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medicina Clinica 医学-医学：内科

CiteScore

3.10

自引率

5.10%

发文量

295

审稿时长

22 days

期刊介绍： Medicina Clínica, fundada en 1943, es una publicación quincenal dedicada a la promoción de la investigación y de la práctica clínica entre los especialistas de la medicina interna, así como otras especialidades. Son características fundamentales de esta publicación el rigor científico y metodológico de sus artículos, la actualidad de los temas y, sobre todo, su sentido práctico, buscando siempre que la información sea de la mayor utilidad en la práctica clínica.